Table 4 Drugs that may regulate the immune checkpoint pathways through targeting ubiquitination/deubiquitination (preclinical)
From: Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways
Type | Name | Target | Preclinical models | References |
|---|---|---|---|---|
Proteasome inhibitors | MG132 | 20S core subunit | In vitro | |
| Â | Epoxomicin | 20S core subunit | In vitro | |
| Â | Lactacystin | 20S core subunit | In vitro | |
E1inhibitors | PYR-41 | ubiquitin E1 enzyme | In vitro | |
E3 agonists | Apple polyphenols | MARCH 1 | THP-1-derived human DCs | |
DUB inhibitors | Curcumin | CSN5 | Breast cancer melanoma colon cancer | |
Others | CDK4/6 inhibitors | Cullin 3SPOP | Prostate cancer | |
| Â | STAT/AKT/ERK inhibitors | c-Cbl, Cbl-b | Lung cancer | |
|  | EGFR inhibitors | GSK3β, β-TrCP | Breast cancer |
